Author

Louisa Lisa Lo

Observed names: L Lo, Lo, Louisa, Lo, Louisa Lisa, Louisa L Lo, Louisa L. Lo, Louisa Lo

Observed institutions: The Royal Melbourne Hospital, The University of Melbourne, Royal Perth Hospital, Peter MacCallum Cancer Centre, Hollywood Private Hospital, Queen Elizabeth Hospital, Victorian Comprehensive Cancer Centre

ORCID: 0000-0001-7426-7953

Observed ORCID: 0000-0001-7426-7953

OpenAlex ID: A5020863678

A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer

2019 · Sheau W. Lok, James R. Whittle, et al. · Cancer Discovery · 152

PDF

Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study

2022 · Peter Savas, Louisa L. Lo, et al. · Cancer Discovery · 62

PDF

Circulating tumour DNA in metastatic breast cancer to guide clinical trial enrolment and precision oncology: A cohort study

2020 · Andjelija Zivanovic Bujak, Chen-Fang Weng, et al. · PLoS Medicine · 33

PDF

VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer

2026 · Sara A. Hurvitz, Rachel M. Layman, et al. · Journal of Clinical Oncology · 28

Tissue factor expression in the metaplasia–adenoma–carcinoma sequence of gastric cancer in a European population

2012 · L Lo, H Valentine, et al. · British Journal of Cancer · 23

PDF

The iPrevent Online Breast Cancer Risk Assessment and Risk Management Tool: Usability and Acceptability Testing

2018 · Louisa L Lo, Ian M Collins, et al. · JMIR Formative Research · 21

PDF

Validation of the IBIS breast cancer risk evaluator for women with lobular carcinoma in-situ

2018 · Louisa Lisa Lo, Roger Laughlin Milne, et al. · British Journal of Cancer · 19

PDF

Pharmacokinetic and pharmacodynamic evaluation of panitumumab in the treatment of colorectal cancer

2015 · Louisa Lo, Dainik Patel, et al. · Expert Opinion on Drug Metabolism & Toxicology · 14

BRAF Mutation Testing and Metastatic Colorectal Cancer in the Community Setting: Is There an Urgent Need for More Education?

2015 · Timothy J. Price, Carol Beeke, et al. · Molecular Diagnosis & Therapy · 7

JSKN003, a biparatopic HER2-targeting ADC, in heavily pretreated HER2-positive breast cancer: A pooled analysis of early-phase studies.

2025 · Yiqun Du, Jian Zhang, et al. · Journal of Clinical Oncology · 6

PDF

BRAF Mutation in Colorectal Cancer

2016 · Louisa Lo, Timothy Price, et al. · InTech eBooks · 4

PDF

Erratum: VIKTORIA-1 Trial of Gedatolisib Plus Fulvestrant With or Without Palbociclib in Hormone Receptor–Positive/HER2−/PIK3CA Wild-Type Advanced Breast Cancer

2026 · Sara A. Hurvitz, Rachel M. Layman, et al. · Journal of Clinical Oncology · 1

PDF

Acceptability and usability of iPrevent, a web-based decision support tool for assessment and management of breast cancer risk

2018 · Phillips, Kelly-Anne, Lo, Louisa, et al. · Figshare · 1

Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study

2023 · Peter Savas, Louisa L. Lo, et al.

Supplementary Data from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study

2023 · Peter Savas, Louisa L. Lo, et al.

Supplementary Figure from Alpelisib Monotherapy for PI3K-Altered, Pretreated Advanced Breast Cancer: A Phase II Study

2023 · Peter Savas, Louisa L. Lo, et al.

PDF

Tables S1-5 from A Phase Ib Dose-Escalation and Expansion Study of the BCL2 Inhibitor Venetoclax Combined with Tamoxifen in ER and BCL2–Positive Metastatic Breast Cancer